drug interactions

Summary

Summary: The action of a drug that may affect the activity, metabolism, or toxicity of another drug.

Top Publications

  1. pmc Acaricide, fungicide and drug interactions in honey bees (Apis mellifera)
    Reed M Johnson
    Department of Entomology, University of Nebraska Lincoln, Lincoln, Nebraska, United States of America
    PLoS ONE 8:e54092. 2013
  2. pmc Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework
    Yoshihiro Yamanishi
    Mines ParisTech, Centre for Computational Biology, 35 rue Saint Honore, F 77305 Fontainebleau Cedex, Institut Curie, F 75248, INSERM U900, F 75248, Paris, France
    Bioinformatics 26:i246-54. 2010
  3. ncbi Clopidogrel with or without omeprazole in coronary artery disease
    Deepak L Bhatt
    Veterans AffairsBoston Healthcare System, Brigham and Women s Hospital, Boston, MA 02132, USA
    N Engl J Med 363:1909-17. 2010
  4. pmc Nonoptimal microbial response to antibiotics underlies suppressive drug interactions
    Tobias Bollenbach
    Department of Systems Biology, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115, USA
    Cell 139:707-18. 2009
  5. pmc Drug interactions and the evolution of antibiotic resistance
    Pamela J Yeh
    Department of Systems Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Rev Microbiol 7:460-6. 2009
  6. pmc Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions
    Jon D Duke
    Regenstrief Institute, Indianapolis, Indiana, United States of America
    PLoS Comput Biol 8:e1002614. 2012
  7. pmc INDI: a computational framework for inferring drug interactions and their associated recommendations
    Assaf Gottlieb
    The Blavatnik School of Computer Science, Tel Aviv University, Tel Aviv, Israel
    Mol Syst Biol 8:592. 2012
  8. ncbi Suboptimal prescribing in older inpatients and outpatients
    J T Hanlon
    Institute for the Study of Geriatric Pharmacotherapy and the Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis 55455, USA
    J Am Geriatr Soc 49:200-9. 2001
  9. ncbi Antibiotic interactions that select against resistance
    Remy Chait
    Department of Systems Biology, Harvard Medical School, 200 Longwood Avenue, Boston, Massachusetts 02115, USA
    Nature 446:668-71. 2007
  10. pmc Systematic exploration of synergistic drug pairs
    Murat Cokol
    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA
    Mol Syst Biol 7:544. 2011

Detail Information

Publications357 found, 100 shown here

  1. pmc Acaricide, fungicide and drug interactions in honey bees (Apis mellifera)
    Reed M Johnson
    Department of Entomology, University of Nebraska Lincoln, Lincoln, Nebraska, United States of America
    PLoS ONE 8:e54092. 2013
    ..Acaricides, antimicrobial drugs and fungicides are not highly toxic to bees alone, but in combination there is potential for heightened toxicity due to interactive effects...
  2. pmc Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework
    Yoshihiro Yamanishi
    Mines ParisTech, Centre for Computational Biology, 35 rue Saint Honore, F 77305 Fontainebleau Cedex, Institut Curie, F 75248, INSERM U900, F 75248, Paris, France
    Bioinformatics 26:i246-54. 2010
    ..There is therefore a strong incentive to develop new methods capable of detecting these potential drug-target interactions efficiently...
  3. ncbi Clopidogrel with or without omeprazole in coronary artery disease
    Deepak L Bhatt
    Veterans AffairsBoston Healthcare System, Brigham and Women s Hospital, Boston, MA 02132, USA
    N Engl J Med 363:1909-17. 2010
    ..Recently, concerns have been raised about the potential for PPIs to blunt the efficacy of clopidogrel...
  4. pmc Nonoptimal microbial response to antibiotics underlies suppressive drug interactions
    Tobias Bollenbach
    Department of Systems Biology, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115, USA
    Cell 139:707-18. 2009
    Suppressive drug interactions, in which one antibiotic can actually help bacterial cells to grow faster in the presence of another, occur between protein and DNA synthesis inhibitors...
  5. pmc Drug interactions and the evolution of antibiotic resistance
    Pamela J Yeh
    Department of Systems Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Rev Microbiol 7:460-6. 2009
    ..Furthermore, theoretical models and new experiments suggest that antagonistic interactions between antibiotics can counteract the evolution of drug resistance...
  6. pmc Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions
    Jon D Duke
    Regenstrief Institute, Indianapolis, Indiana, United States of America
    PLoS Comput Biol 8:e1002614. 2012
    Drug-drug interactions (DDIs) are a common cause of adverse drug events. In this paper, we combined a literature discovery approach with analysis of a large electronic medical record database method to predict and evaluate novel DDIs...
  7. pmc INDI: a computational framework for inferring drug interactions and their associated recommendations
    Assaf Gottlieb
    The Blavatnik School of Computer Science, Tel Aviv University, Tel Aviv, Israel
    Mol Syst Biol 8:592. 2012
    Inferring drug-drug interactions (DDIs) is an essential step in drug development and drug administration...
  8. ncbi Suboptimal prescribing in older inpatients and outpatients
    J T Hanlon
    Institute for the Study of Geriatric Pharmacotherapy and the Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis 55455, USA
    J Am Geriatr Soc 49:200-9. 2001
    ..Future research is necessary to measure and test other methods for tackling this major public health problem facing older people...
  9. ncbi Antibiotic interactions that select against resistance
    Remy Chait
    Department of Systems Biology, Harvard Medical School, 200 Longwood Avenue, Boston, Massachusetts 02115, USA
    Nature 446:668-71. 2007
    ..of the fitness landscape for the evolution of resistance and point to a trade-off between the effect of drug interactions on absolute potency and the relative competitive selection that they impose on emerging resistant populations...
  10. pmc Systematic exploration of synergistic drug pairs
    Murat Cokol
    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA
    Mol Syst Biol 7:544. 2011
    ..While many drug synergies correspond to genetic interactions, the majority of drug synergies appear to result from non-specific promiscuous synergy...
  11. pmc Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis
    Rene Rizzoli
    Division of Bone Disease, Department of Rehabilitation and Geriatrics, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
    Calcif Tissue Int 89:91-104. 2011
    ..The aim of this review is to explore the risk of adverse drug reactions and drug-drug interactions with treatments for postmenopausal osteoporosis...
  12. pmc SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions
    Saskia Preissner
    Structural Bioinformatics Group, Institute of Physiology, Charite University Medicine Berlin, Arnimallee 22, 14197 Berlin, Germany
    Nucleic Acids Res 38:D237-43. 2010
    ..SuperCYP is meant to be a platform and a starting point for scientists and health professionals for furthering their research...
  13. ncbi Ageing with HIV: medication use and risk for potential drug-drug interactions
    Catia Marzolini
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    J Antimicrob Chemother 66:2107-11. 2011
    To compare the use of co-medication, the potential drug-drug interactions (PDDIs) and the effect on antiretroviral therapy (ART) tolerability and efficacy in HIV-infected individuals according to age, ≥ 50 years or <50 years.
  14. ncbi Physicians' decisions to override computerized drug alerts in primary care
    Saul N Weingart
    Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Rose 112, 330 Brookline Avenue, Boston, MA 02215, USA
    Arch Intern Med 163:2625-31. 2003
    ..Although computerized physician order entry reduces medication errors among inpatients, little is known about the use of this system in primary care...
  15. ncbi Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy
    Andrew Boulle
    School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
    JAMA 300:530-9. 2008
    ..Rifampicin-based antitubercular therapy reduces the plasma concentrations of nevirapine and efavirenz. The virological consequences of these interactions are not well described...
  16. ncbi Clinically significant drug interactions with newer antidepressants
    Edoardo Spina
    Section of Pharmacology, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy
    CNS Drugs 26:39-67. 2012
    ..treat co-morbid psychiatric or somatic disorders, they are likely to be involved in clinically significant drug interactions. This review examines the drug interaction profiles of the following newer antidepressants: escitalopram, ..
  17. ncbi Using a shallow linguistic kernel for drug-drug interaction extraction
    Isabel Segura-Bedmar
    Computer Science Department, Carlos III University of Madrid, Leganes, Spain
    J Biomed Inform 44:789-804. 2011
    ..care professionals with an interesting way to reduce time spent reviewing the literature for potential drug-drug interactions. Nevertheless, no approach has been proposed to the problem of extracting DDIs in biomedical texts...
  18. ncbi Synergy and other interactions in phytomedicines
    E M Williamson
    The School of Pharmacy, University of London, United Kingdom
    Phytomedicine 8:401-9. 2001
    ..Herbs discussed include Ginkgo biloba, Piper methysticum (Kava-Kava), Glycyrrhiza glabra, Hypericum perforatum, Valeriana officinalis, Cannabis sativa, Salix alba and others...
  19. pmc Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States
    Dima M Qato
    Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA
    JAMA 300:2867-78. 2008
    ..Despite concerns about drug safety, current information on older adults' use of prescription and over-the-counter medications and dietary supplements is limited...
  20. pmc Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins
    Tsuyoshi Minematsu
    Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, 1550 4th Street, San Francisco, CA 94158, USA
    Mol Cancer Ther 10:531-9. 2011
    ..The study provides the basis for further clinical DDI studies with TKIs...
  21. ncbi Drug interactions at GABA(A) receptors
    Esa R Korpi
    Department of Pharmacology and Clinical Pharmacology, University of Turku, Itainen Pitkakatu 4B, Finland
    Prog Neurobiol 67:113-59. 2002
    ....
  22. pmc Discovering drug-drug interactions: a text-mining and reasoning approach based on properties of drug metabolism
    Luis Tari
    Disease and Translational Informatics, Hoffmann La Roche, Nutley, NJ 07110, USA
    Bioinformatics 26:i547-53. 2010
    Identifying drug-drug interactions (DDIs) is a critical process in drug administration and drug development...
  23. pmc Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity
    Brandon Swift
    University of North Carolina at Chapel Hill, 27599 7569, USA
    Drug Metab Rev 42:446-71. 2010
    ..hepatobiliary drug transport, species differences in drug transport, transport protein regulation, drug-drug interactions, and hepatotoxicity...
  24. ncbi Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population
    Jean B Nachega
    Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
    AIDS 26:S39-53. 2012
    ..The combination of ART with polypharmacy significantly increases the chance of potentially serious drug-drug interactions (DDIs), which can lead to drug toxicity, poorer ART adherence, loss of efficacy of the coadministered ..
  25. ncbi The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective
    Thorir D Bjornsson
    Wyeth, Collegeville, Pennsylvania, USA
    Drug Metab Dispos 31:815-32. 2003
    ..While existing guidances cover mainly P450-mediated drug interactions, the importance of other mechanisms, such as transporters, has been recognized more recently, and should ..
  26. pmc High-priority drug-drug interactions for use in electronic health records
    Shobha Phansalkar
    Division of General Internal Medicine and Primary Care, Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Am Med Inform Assoc 19:735-43. 2012
    To develop a set of high-severity, clinically significant drug-drug interactions (DDIs) for use in electronic health records (EHRs).
  27. ncbi Comparison of critical drug-drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia
    E L Olvey
    Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, Arizona, USA
    Clin Pharmacol Ther 87:48-51. 2010
    ..was to evaluate the agreement among the US Department of Veterans Affairs (VA) listing of "critical" drug-drug interactions (DDIs) and two standard drug-interaction compendia...
  28. pmc Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor
    Jiezhong Chen
    Faculty of Science, Technology and Engineering, La Trobe University, School of Pharmacy, Bendigo, VIC 3550, Australia
    Ann Clin Microbiol Antimicrob 5:3. 2006
    ..an important drug in the treatment of tuberculosis, is used extensively despite its broad effects on drug-drug interactions, creating serious problems...
  29. ncbi Adverse drug interactions involving common prescription and over-the-counter analgesic agents
    Elliot V Hersh
    Department of Oral Surgery and Pharmacology, University of Pennsylvania School of Dental Medicine, Philadelphia, Pennsylvania 19104 6030, USA
    Clin Ther 29:2477-97. 2007
    ..In addition, an estimated 36 million Americans use over-the-counter (OTC) analgesics daily. Given this volume of use, it is not surprising that a number of drug interactions involving analgesic drugs have been reported.
  30. pmc Tricyclic antidepressant pharmacology and therapeutic drug interactions updated
    P K Gillman
    PsychoTropical Research, Bucasia, Queensland, Australia
    Br J Pharmacol 151:737-48. 2007
    ..Standard texts (e.g. the British National Formulary) and treatment guidelines would benefit by taking account of these new data and understandings...
  31. ncbi Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport
    Juergen Kindla
    Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen Nuremberg, Erlangen, Germany
    Drug Metab Dispos 39:1047-53. 2011
    ..more drugs that are substrates for these hepatic uptake transporters may lead to transporter-mediated drug-drug interactions, resulting in altered transport kinetics for drug substrates...
  32. pmc An enhanced Petri-net model to predict synergistic effects of pairwise drug combinations from gene microarray data
    Guangxu Jin
    Systems Medicine and Bioengineering Department, Cornell University, Houston, TX 77030, USA
    Bioinformatics 27:i310-6. 2011
    ..In this article, we propose an enhanced Petri-Net (EPN) model to recognize the synergistic effects of drug combinations from the molecular response profiles, i.e. drug-treated microarray data...
  33. ncbi Systems biology analysis of protein-drug interactions
    Jacques Colinge
    Research Center for Molecular Medicine of the Austrian Academy of Sciences CeMM, Jacques Colinge, Vienna, Austria
    Proteomics Clin Appl 6:102-16. 2012
    ....
  34. ncbi Hospital admissions resulting from preventable adverse drug reactions
    Patrick J McDonnell
    School of Pharmacy, Temple University, Philadelphia, PA 19140 5101, USA
    Ann Pharmacother 36:1331-6. 2002
    ..Adverse drug reactions (ADRs) are a significant cause of hospital admissions. These events can lead to significant morbidity and mortality and financial costs. ADRs that may be preventable might be considered a form of medication error...
  35. ncbi Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update
    Edoardo Spina
    Section of Pharmacology, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy
    Clin Ther 30:1206-27. 2008
    ..Rather, concern about drug interactions with second-generation antidepressants is based on their in vitro potential to inhibit > or = 1 CYP ..
  36. pmc Impact of OATP transporters on pharmacokinetics
    A Kalliokoski
    Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland
    Br J Pharmacol 158:693-705. 2009
    ..Some drugs may inhibit OATP transporters (e.g. cyclosporine) causing pharmacokinetic drug-drug interactions. Moreover, genetic variability in genes encoding OATP transporters can result in marked inter-individual ..
  37. pmc Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels
    N P Tatonetti
    Biomedical Informatics Training Program, Stanford University, Stanford, California, USA
    Clin Pharmacol Ther 90:133-42. 2011
    ..In contrast, neither drug administered singly was associated with such changes in glucose levels. An increase in glucose levels is not a general effect of combined therapy with selective serotonin reuptake inhibitors (SSRIs) and statins...
  38. pmc A systems biology approach to identify effective cocktail drugs
    Zikai Wu
    Institute of Systems Biology, Shanghai University, Shanghai, China
    BMC Syst Biol 4:S7. 2010
    ..However, most of existing combination drugs are developed based on clinical experience or test-and-trial strategy, which are not only time consuming but also expensive...
  39. ncbi Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions
    Anthony E Zimmermann
    Massachusetts College of Pharmacy and Health Science, Worcester, Massachusetts, USA
    Clin Infect Dis 42:283-90. 2006
    ..Tenofovir is associated with multiple drug interactions, leading to an increased risk of ARF...
  40. ncbi Drug-drug interactions among elderly patients hospitalized for drug toxicity
    David N Juurlink
    Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    JAMA 289:1652-8. 2003
    Drug-drug interactions are a preventable cause of morbidity and mortality, yet their consequences in the community are not well characterized.
  41. pmc Potential drug-drug and drug-disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico City
    Svetlana Vladislavovna Doubova Dubova
    Epidemiology and Health Services Research Unit, National Medical Center Century XXI, Mexican Institute of Social Security, Mexico City, Mexico
    BMC Health Serv Res 7:147. 2007
    ..In addition, we aimed to identify the associated factors for these interactions...
  42. ncbi MDR- and CYP3A4-mediated drug-herbal interactions
    Dhananjay Pal
    School of Pharmacy, University of Missouri Kansas City, Kansas City, MO 64110 2499, USA
    Life Sci 78:2131-45. 2006
    ..In vitro screening techniques will play a major role in identifying possible herb-drug interactions and thus create a platform for clinical studies to emerge...
  43. pmc Networks from drug-drug surfaces
    Pamela Yeh
    Department of Systems Biology, Harvard Medical School, Boston, MA, USA
    Mol Syst Biol 3:85. 2007
  44. ncbi Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions
    Yoshihisa Shitara
    Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1 8 1, Inohana, Chuo Ku, Chiba 260 8675, Japan
    Pharmacol Ther 112:71-105. 2006
    ..To avoid a pharmacokinetic alteration, we need to have information about the metabolizing enzyme(s) and transporter(s) involved in the pharmacokinetics of statins and, along with such information, model-based prediction is also useful...
  45. ncbi Safety of statins: focus on clinical pharmacokinetics and drug interactions
    Stefano Bellosta
    Department of Pharmacological Sciences, University of Milan, Milan, Italy
    Circulation 109:III50-7. 2004
    ..This review summarizes the pharmacokinetic properties of statins and emphasizes their clinically relevant drug interactions.
  46. pmc A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports
    Nicholas P Tatonetti
    Biomedical Informatics Training Program, Stanford University, Stanford, California, USA
    J Am Med Inform Assoc 19:79-85. 2012
    Adverse drug events (ADEs) are common and account for 770 000 injuries and deaths each year and drug interactions account for as much as 30% of these ADEs...
  47. ncbi Orlistat-associated adverse effects and drug interactions: a critical review
    Theodosios D Filippatos
    Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece
    Drug Saf 31:53-65. 2008
    ..This review considers orlistat-related adverse effects and drug interactions. The clinical relevance and pathogenesis of these effects is also discussed.
  48. ncbi Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors
    Larry K Golightly
    University of Colorado Hospital, Aurora, CO 80045, USA
    Clin Pharmacokinet 51:501-14. 2012
    ..Accordingly, the number of clinically significant drug-drug interactions associated with these agents is minimal, with only saxagliptin necessitating dose adjustment if administered ..
  49. ncbi Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department
    C M Hohl
    McGill University Royal College Emergency Medicine Residency Training Program, Sir Mortimer B Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Ann Emerg Med 38:666-71. 2001
    ..drug-related events (ADREs) leading to emergency department presentation that were recognized by emergency physicians, and the frequency of potential adverse drug interactions (PADIs) in medication regimens of elderly patients in the ED.
  50. ncbi P-glycoprotein related drug interactions: clinical importance and a consideration of disease states
    Caroline A Lee
    Pfizer Global Research and Development, Department of Pharmacokinetics, Dynamics and Metabolism, 10646 Science Center Drive, San Diego, CA 92121, USA
    Expert Opin Drug Metab Toxicol 6:603-19. 2010
    ..Clinically significant P-gp related drug interactions appear restricted to digoxin...
  51. pmc Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems
    Kirsten K Viktil
    Diakonhjemmet Hospital Pharmacy, Faculty of Medicine, University of Oslo, Oslo, Norway
    Br J Clin Pharmacol 63:187-95. 2007
    ..To investigate whether polypharmacy defined as a definite number of drugs is a suitable indicator for describing the risk of occurrence of drug-related problems (DRPs) in a hospital setting...
  52. ncbi In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor
    Melinda J Reese
    Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Drug Metab Dispos 41:353-61. 2013
    ..investigated the in vitro drug transport and metabolism of DTG and assessed the potential for clinical drug-drug interactions. DTG is a substrate for the efflux transporters P-glycoprotein (Pgp) and human breast cancer resistance ..
  53. pmc Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions
    Buster Mannheimer
    Karolinska Institutet, Department of Internal Medicine at Södersjukhuset, Stockholm, Sweden
    Br J Clin Pharmacol 69:411-7. 2010
    The study aimed to investigate the clinical adherence to drug label recommendations on important drug-drug interactions (DDIs)...
  54. pmc Ability of pharmacy clinical decision-support software to alert users about clinically important drug-drug interactions
    Kim R Saverno
    Department of Pharmacy Practice and Science, The University of Arizona College of Pharmacy, Tucson, Arizona 85721 0202, USA
    J Am Med Inform Assoc 18:32-7. 2011
    ..However, studies indicate these systems may miss some important interactions. The purpose of this study was to assess the performance of pharmacy CDS programs to detect clinically important DDIs...
  55. ncbi Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole
    Jenny Y Chien
    Department of Drug Disposition, Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Drug Metab Dispos 34:1208-19. 2006
    Conventional methods to forecast CYP3A-mediated drug-drug interactions have not employed stochastic approaches that integrate pharmacokinetic (PK) variability and relevant covariates to predict inhibition in terms of probability and ..
  56. ncbi Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis
    Catherine Boulanger
    University of Miami School of Medicine, Miami, USA
    Clin Infect Dis 49:1305-11. 2009
    Human immunodeficiency virus (HIV)-associated tuberculosis is difficult to treat, given the propensity for drug interactions between the rifamycins and the antiretroviral drugs...
  57. ncbi ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions
    Béatrice Marquez
    Pharmacologie Cellulaire et Moléculaire, Louvain Drug Research Institute, Universite Catholique de Louvain, B 1200 Brussels, Belgium
    Curr Drug Targets 12:600-20. 2011
    ..Again, this mechanism reinforces drug interactions mediated by cytochrome P450 inhibition, as many substrates of P-glycoprotein and CYP3A4 are common...
  58. ncbi Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study
    Catia Marzolini
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
    Antivir Ther 15:413-23. 2010
    Potential drug-drug interactions (PDDIs) might expand with new combination antiretroviral therapies (ART) and polypharmacy related to increasing age and comorbidities...
  59. pmc Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children
    Jane Achan
    Department of Pediatrics and Child Health, Makerere University College of Health Sciences, Kampala, Uganda
    N Engl J Med 367:2110-8. 2012
    ....
  60. ncbi Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy
    J J Gagne
    Department of Health Policy, Jefferson Medical College, Philadelphia, PA 19107, USA
    J Clin Pharm Ther 33:141-51. 2008
    Drug-drug interactions (DDIs) are preventable medication errors associated with potentially serious adverse events and death. Several studies have examined the prevalence of potential DDIs among ambulatory patients in various countries...
  61. ncbi Relative potencies and combination effects of steroidal estrogens in fish
    Karen L Thorpe
    School of Biological Sciences, The Hatherly Laboratory, Exeter University, The Prince of Wales Road, Exeter, Devon, EX4 4PS, UK
    Environ Sci Technol 37:1142-9. 2003
    ....
  62. ncbi Stereoselectivity of human cytochrome p450 in metabolic and inhibitory activities
    Toshiro Niwa
    Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Higashi Tamagawa Gakuen, Machida, Tokyo, Japan
    Curr Drug Metab 12:549-69. 2011
    ..The present information gives insight into the contribution of stereoselectivity to metabolism mediated by P450s and the risk of adverse drug-drug interactions due to stereoselectivity.
  63. ncbi Panax ginseng: a systematic review of adverse effects and drug interactions
    Joanna Thompson Coon
    Department of Complementary Medicine, School of Postgraduate Medicine and Health Sciences, University of Exeter, Exeter, United Kingdom
    Drug Saf 25:323-44. 2002
    ..All articles containing original data on adverse events and drug interactions with P. ginseng were included...
  64. ncbi Analysis of drug interactions
    Irene V Bijnsdorp
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Methods Mol Biol 731:421-34. 2011
    ..Here, we describe how combinations can be designed in vitro and how to analyze them using Calcusyn or Compusyn. Moreover, pitfalls, limitations, and advantages of using these combinations and Calcusyn/Compusyn are described...
  65. ncbi Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation
    M Schmidt
    Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
    Aliment Pharmacol Ther 35:165-74. 2012
    ..Cytochrome P450 inhibition by proton pump inhibitors (PPIs) may attenuate the effectiveness of clopidogrel...
  66. doi Have physiologically-based pharmacokinetic models delivered?
    Andrea N Edginton
    Expert Opin Drug Metab Toxicol 7:929-34. 2011
    ..More importantly, increased training along with managerial and regulatory support is imperative to the continued integration of PBPK modeling in both HHRA and DD...
  67. ncbi Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies
    D J Angiolillo
    Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, USA
    Clin Pharmacol Ther 89:65-74. 2011
    ..7, 27.1, 19.0 (P < 0.0001), and 3.9% (P = 0.3319), respectively. The results suggest that a metabolic drug-drug interaction exists between clopidogrel and omeprazole but not between clopidogrel and pantoprazole...
  68. pmc Predicting Anatomical Therapeutic Chemical (ATC) classification of drugs by integrating chemical-chemical interactions and similarities
    Lei Chen
    College of Information Engineering, Shanghai Maritime University, Shanghai, China
    PLoS ONE 7:e35254. 2012
    ....
  69. ncbi MDR- and CYP3A4-mediated drug-drug interactions
    Dhananjay Pal
    Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri Kansas City, 5005 Rockhill Road, Kansas City, MO 64110 2499, USA
    J Neuroimmune Pharmacol 1:323-39. 2006
    ..Multidrug regimens and corresponding drug-drug interactions are known to cause many adverse drug reactions and treatment failures...
  70. ncbi Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement
    Martin Schaefer
    Department of Psychiatry and Psychotherapy, Charite Universitatsmedizin Berlin, Campus Charite Mitte, Berlin, Germany
    J Hepatol 57:1379-90. 2012
    ..Furthermore, because of possible drug-drug interactions, new antivirals administered together with PegIFNα and ribavirin may complicate psychiatric side effect ..
  71. ncbi Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel?
    Alberto Corsini
    Department of Pharmacological Sciences, University of Milan, Italy
    Curr Med Res Opin 27:1551-62. 2011
    ..at high cardiovascular risk and with multiple comorbid conditions increases, so does the potential for drug-drug interactions (DDIs)...
  72. ncbi A dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experience
    L Waters
    Department of GU HIV Medicine, Chelsea and Westminster Hospital, London, UK
    Int J STD AIDS 23:546-52. 2012
    ..Patients undergo a full medication and drug interactions review, neurocognitive assessment, adherence self-assessment and investigations including therapeutic drug ..
  73. ncbi Protein dynamics in drug combinations: a linear superposition of individual-drug responses
    Naama Geva-Zatorsky
    Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel
    Cell 140:643-51. 2010
    ..Our approach might eliminate the need to increase the number of experiments exponentially with the number of drugs and suggests that it might be possible to rationally control protein dynamics with specific drug combinations...
  74. ncbi Update on the pharmacogenomics of proton pump inhibitors
    Krisztina Hagymasi
    Semmelweis University, II Department of Internal Medicine, 1088 Budapest, Szentkiralyi u 46, Hungary
    Pharmacogenomics 12:873-88. 2011
    ....
  75. ncbi Electronic drug interaction alerts in ambulatory care: the value and acceptance of high-value alerts in US medical practices as assessed by an expert clinical panel
    Saul N Weingart
    Center for Patient Safety, Dana Farber Cancer Institute, Boston, MA, USA
    Drug Saf 34:587-93. 2011
    ..Computerized physician order entry systems are known to improve patient safety in acute-care hospitals. However, as clinicians frequently override drug interaction and allergy alerts, their value in ambulatory care remains uncertain...
  76. pmc Factors influencing alert acceptance: a novel approach for predicting the success of clinical decision support
    Hanna M Seidling
    Division of General Medicine and Primary Care, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Med Inform Assoc 18:479-84. 2011
    ..The clinical effectiveness of these systems, however, is substantially limited by poor user acceptance of presented warnings. To enhance alert acceptance it may be useful to quantify the impact of potential modulators of acceptance...
  77. pmc A linguistic rule-based approach to extract drug-drug interactions from pharmacological documents
    Isabel Segura-Bedmar
    Computer Science Department, University Carlos III of Madrid, Leganes, 28911, Spain
    BMC Bioinformatics 12:S1. 2011
    ..The increasing volume of the scientific literature overwhelms health care professionals trying to be kept up-to-date with all published studies on DDI...
  78. ncbi General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information
    Yoshiyuki Ohno
    Department of Pharmacy, University of Tokyo Hospital, Faculty of Medicine, University of Tokyo, Tokyo, Japan
    Clin Pharmacokinet 47:669-80. 2008
    ..Although the prediction of drug-drug interactions (DDIs) that are mediated by induction of CYP3A4 has been performed mainly on the basis of in vitro ..
  79. ncbi Duloxetine: clinical pharmacokinetics and drug interactions
    Mary Pat Knadler
    Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Clin Pharmacokinet 50:281-94. 2011
    ..While duloxetine is generally well tolerated, it is important to be knowledgeable about the potential for pharmacokinetic interactions between duloxetine and drugs that inhibit CYP1A2 or drugs that are metabolized by CYP2D6 enzymes...
  80. ncbi Statin-induced myopathy: the two faces of Janus
    Rohit Arora
    Division of Cardiovascular Disease, Department of Medicine, Chicago Medical School, 3001 Green Bay Road, North Chicago, IL 60064, USA
    J Cardiovasc Pharmacol Ther 11:105-12. 2006
    ..The mechanism of statin-associated myotoxicity has not been satisfactorily defined and is likely due to multiple factors, including membrane instability, mitochondrial dysfunction, and defects in myocyte duplication...
  81. ncbi Interactions between different selenium compounds and zinc, cadmium and mercury
    Giorgio Feroci
    Institute of Chemical Sciences, University of Bologna, Via S Donato 15, 40127 Bologna, Italy
    J Trace Elem Med Biol 18:227-34. 2005
    ..Overall equilibrium constants for complex formation (Kf) and the solubility product (Ksp) for poorly soluble species are also reported...
  82. pmc Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects
    Susan L Ford
    Clinical Pharmacology and Discovery Medicine, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Antimicrob Agents Chemother 52:534-8. 2008
    ..Based on the results of this study, a reduction in the RFB dose by > or =75% (to 150 mg QOD or three times per week) is recommended when it is coadministered with FPV-RTV (700/100 mg BID)...
  83. ncbi Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors
    Tiina Jaakkola
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Basic Clin Pharmacol Toxicol 99:44-51. 2006
    ....
  84. ncbi Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane
    Yi Lisa Lyu
    Department of Pharmacology, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, Piscataway, New Jersey 08854 5635, USA
    Cancer Res 67:8839-46. 2007
    ....
  85. pmc Drug interactions modulate the potential for evolution of resistance
    Jean Baptiste Michel
    Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 105:14918-23. 2008
    ..This framework reveals the central role of drug epistasis in the evolution of resistance and points to new strategies for combating the emergence of drug-resistant bacteria...
  86. ncbi Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers
    W Ridtitid
    Department of Pharmacology, Faculty of Science, Prince of Songkla University, Hat Yai, Thailand
    J Pharm Pharmacol 52:1265-9. 2000
    ..Simultaneous use of rifampin and mefloquine should be avoided to optimize the therapeutic efficacy of mefloquine and prevent the risk of Plasmodium falciparum resistance in malarial treatment...
  87. ncbi Joint algal toxicity of 16 dissimilarly acting chemicals is predictable by the concept of independent action
    M Faust
    Department of Biology and Chemistry, University of Bremen, D 28334 Bremen, Germany
    Aquat Toxicol 63:43-63. 2003
    ..With a regulatory perspective, however, fulfilment of both conditions may be regarded as an extraordinary situation, and hence concentration addition may be defendable as a pragmatic and precautionary default assumption...
  88. ncbi MCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase-, but not ERK1/2-dependent pathway
    Megumi Hiraoka
    Department of Medical Biochemistry, Graduate School of Medicine, Tokyo Medical and Dental University, 1 5 45 Yushima Building D 256, Bunkyo, Tokyo 113 8519, Japan
    Life Sci 75:1333-41. 2004
    ..These findings indicate a role for pitavastatin in modulating the MCP-1-induced phenotypic changes of monocyte-endothelial interactions, which may account for the anti-inflammatory effects of statins...
  89. ncbi Plasma concentrations of active simvastatin acid are increased by gemfibrozil
    J T Backman
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Finland
    Clin Pharmacol Ther 68:122-9. 2000
    ..The aim of this study was to determine whether gemfibrozil affects the pharmacokinetics of simvastatin and whether it affects CYP3A4 activity in vitro...
  90. ncbi On the mechanism of antidepressant-like action of berberine chloride
    Shrinivas K Kulkarni
    Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India
    Eur J Pharmacol 589:163-72. 2008
    ..Further, nitric oxide pathway and/or sigma receptors are involved in mediating its antidepressant-like activity in mouse forced swim test...
  91. ncbi Chronic morphine accelerates the progression of lipopolysaccharide-induced sepsis to septic shock
    Frank M Ocasio
    Department of Biology, Seton Hall University, 400 South Orange Avenue, South Orange, NJ 07079, USA
    J Neuroimmunol 149:90-100. 2004
    ..Our study presents both the molecular and cellular mechanisms underlying the potentiated LPS-induced inflammation and accelerated progression to septic shock seen with chronic morphine exposure...
  92. ncbi Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug
    K S Fenner
    Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Sandwich, UK
    Clin Pharmacol Ther 85:173-81. 2009
    ..and in vitro inhibition of digoxin were examined to predict the P-glycoprotein (P-gp) component of drug-drug interactions. Coadministered drugs (co-meds) in clinical trials (N = 123) resulted in a small, <or=100% increase in ..
  93. ncbi Effect of sildenafil on the anticonvulsant action of classical and second-generation antiepileptic drugs in maximal electroshock-induced seizures in mice
    Dorota Nieoczym
    Department of Animal Physiology, Institute of Biology, Maria Curie Skłodowska University, Lublin, Poland
    Epilepsia 51:1552-9. 2010
    ....
  94. pmc Predicting drug-drug interactions: an FDA perspective
    Lei Zhang
    Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Rm 3188, Bldg 51, 10903 New Hampshire Avenue, Silver Spring, Maryland 20993, USA
    AAPS J 11:300-6. 2009
    Pharmacokinetic drug interactions can lead to serious adverse events, and the evaluation of a new molecular entity's drug-drug interaction potential is an integral part of drug development and regulatory review prior to its market ..
  95. pmc Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review
    Elinore F McCance-Katz
    Department of Psychiatry, University of California, San Francisco, San Francisco, California, USA
    Am J Addict 19:4-16. 2010
    b>Drug interactions are a leading cause of morbidity and mortality. Methadone and buprenorphine are frequently prescribed for the treatment of opioid addiction...
  96. ncbi Concordance of severity ratings provided in four drug interaction compendia
    Jacob Abarca
    Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson 85721 0207, USA
    J Am Pharm Assoc (2003) 44:136-41. 2004
    ..To evaluate the agreement among drug-drug interaction (DDI) compendia as to designation of interactions as having the greatest clinical importance ("major" DDIs)...
  97. ncbi Drug interaction studies: study design, data analysis, and implications for dosing and labeling
    S M Huang
    Office of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA
    Clin Pharmacol Ther 81:298-304. 2007
    ..In the past 10 years, clinical pharmacology guidances covering important areas have been issued, including pharmacokinetic data in patients with renal and hepatic impairment, dose-response studies, and drug-drug interactions.
  98. ncbi Overrides of medication alerts in ambulatory care
    Thomas Isaac
    Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA
    Arch Intern Med 169:305-11. 2009
    ..Electronic prescribing systems with decision support may improve patient safety in ambulatory care by offering drug allergy and drug interaction alerts. However, preliminary studies show that clinicians override most of these alerts...
  99. ncbi Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions
    Liana Urichuk
    Regional Mental Health Program, Capital Health, University of Alberta, Edmonton, Alberta, Canada
    Curr Drug Metab 9:410-8. 2008
    ..paliperidone and amisulpride is reviewed, and the possible relevance of this metabolism to drug-drug interactions is discussed...
  100. ncbi Potential drug-drug interactions within Veterans Affairs medical centers
    Maysaa Mahmood
    Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona UA, Tucson, AZ 85721 0202, USA
    Am J Health Syst Pharm 64:1500-5. 2007
    This study assessed the prevalence of 25 clinically important drug-drug interactions (DDIs) in the ambulatory care clinics of the Department of Veterans Affairs medical centers (VAMCs).
  101. ncbi High confidence predictions of drug-drug interactions: predicting affinities for cytochrome P450 2C9 with multiple computational methods
    Matthew G Hudelson
    Department of Mathematics, Washington State University, Pullman, WA 99164 3113, USA
    J Med Chem 51:648-54. 2008
    ..When all of these methods agree, the predictive accuracy is 94%. An external validation set of 11 compounds gives a predictive accuracy of 91% when all methods agree...

Research Grants75

  1. Multi-targeted Countermeasures against Acute and Delayed Effects of OP Exposure
    John A Butera; Fiscal Year: 2013
    ..as opposed to co-administering two drugs where development metrics are complicated due to possible drug-drug interactions and differential kinetic profiles...
  2. Drug Interactions at the Human Blood-Brain Barrier
    Jashvant D Unadkat; Fiscal Year: 2010
    ..of drugs to treat lethal CNS disorders such as brain tumors or to produce profound, but inadvertent, drug interactions (Aim 1)? A negative answer will also be significant in that it will guide clinicians as well as the ..
  3. Microsomal Cytochromes P450 and their Interactions with their Redox Partners
    Lucy A Waskell; Fiscal Year: 2013
    ..Xenobiotic metabolizing cyts P450 are also responsible for the majority of drug-drug interactions and adverse drug reactions...
  4. Dual Direct Inhibitors of Thrombin and Factor Xa
    UMESH RAMANLAL DESAI; Fiscal Year: 2012
    ..reactions including enhanced bleeding risk, immunological reaction, genetic variation in metabolism, food or drug interactions and liver toxicity...
  5. The Role of Alcohol in HIV Therapy Hepatotoxicity
    Craig J McClain; Fiscal Year: 2012
    ..SO#1 and clinical hepatotoxicity risk), on the development and progression of hepatotoxicity in mice and the drug interactions with chronic alcohol intake;and 3...
  6. Optimizing Chronic Disease Prevention and Management in Advanced Dementia
    Jennifer Tjia; Fiscal Year: 2010
    ..drugs may not be consistent with goals of care, increase the risk of adverse drug events and drug-drug interactions, are costly, and contribute to polypharmacy...
  7. Double Humanization of Liver and Blood in Mice
    ELIZABETH MARIE WILSON; Fiscal Year: 2012
    ..drug metabolism and pharmacokinetics, drug-drug interactions, toxicology and gene therapy among others...
  8. HEPATIC DEGRADATION OF CYTOCHROME P450 ENZYMES
    Maria Almira Correia; Fiscal Year: 2013
    ..Such drug-mediated modulation of P450 content can significantly influence clinical drug-drug interactions (DDIs)...
  9. NOVEL HIGH THROUGHPUT PLATFORM FOR SCREENING CYTOCHROME P450 INDUCTION
    MARIA INES MORANO; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Many prescribed drugs exhibit drug-drug interactions due to up-regulation or inhibition of specific P450 enzymes...
  10. Biophysics of Drug Interactions with Viral Episomes
    James K Bashkin; Fiscal Year: 2013
    ....
  11. Development of Transdermal Films for the the Delivery of HIV Therapeutics
    Anthony Sang Won Ham; Fiscal Year: 2010
    ..However, the side-effects, toxicity, and drug-drug interactions of HAART therapies have resulted in reduced patient adherence to the drug regimens, fueling the development ..
  12. Participation in Cytochrome b5 in Anesthetic Metabolism
    Lucy A Waskell; Fiscal Year: 2010
    ..Xenobiotic metabolizing cyts P450 are also responsible for the majority of drug-drug interactions and adverse drug reactions...
  13. Structure-Based Design of Novel HNF4a Antagonists to Treat Metabolic Syndrome
    Arnold T Hagler; Fiscal Year: 2010
    ..Although drugs do exist for the individual components, complications due to drug interactions, side effects, and the sheer number of drugs that are needed, along with the serious consequences of the ..
  14. Inhibition of Carboxylesterase Metabolism by Ethanol
    Robert B Parker; Fiscal Year: 2011
    ..b>Drug interactions involving inhibition of cytochrome P450 enzymes are well known causes of adverse drug events...
  15. Global Proteomic Screening by MALDI Spectrometric Imaging of Protein-Bead Arrays
    Mark Lim; Fiscal Year: 2012
    ..interaction analysis both with PC-Mass-Tags and by label-free means, detection of label-free protein-drug interactions, detection of protein modifications and serum profiling for cancer biomarker discovery...
  16. FUNCTIONAL ANALYSIS OF NUCLEAR RECEPTOR VARIANTS
    Curtis J Omiecinski; Fiscal Year: 2013
    ..the variant CARs have critical functional implications for human health, determining outcomes such as drug-drug interactions, drug and bile acid induced hepatotoxicity, carcinogen and steroid metabolism, and the regulation of lipid ..
  17. Prostate Cancer Prevention by Diallyl Trisulfide
    Shivendra Singh; Fiscal Year: 2013
    ..2) is essential for optimization of DATS-based chemopreventive regimens to eliminate potential adverse drug-drug interactions between DATS and other anti- oxidants or agents interfering with iron homeostasis...
  18. Function and regulation of OATP1B1 and OATP1B3
    Wei Yue; Fiscal Year: 2013
    ..are now recognized as clinically relevant determinants of variable drug responsiveness and unexpected drug-drug interactions. Organic anion transporting polypeptides (OATP) 1B1 and OATP1B3 are liver-specific, and are major uptake ..
  19. A 3D biomimetic liver sinusoid construct for predicting physiology and toxicity
    Martin L Yarmush; Fiscal Year: 2013
    ..The liver plays a central role in human drug interactions, both within the liver and in other organs, as a result of drug metabolism...
  20. Xenobiotic sensors PXR and CAR and regulation of the UGT1 locus
    Robert H Tukey; Fiscal Year: 2012
    ..This application is the first attempt to investigate how human UGTs are regulated in mice, and to apply this animal to understand the impact of glucuronidation towards drug-drug interactions, drug metabolism and eventually disease.
  21. Novel Antifungal Therapeutic Approaches
    Joseph Heitman; Fiscal Year: 2012
    ..Nonimmunosuppressive analogs that retain antifungal activity were identified. Synergistic fungicidal drug interactions were demonstrated and mechanisms of action elucidated...
  22. Vitamin D Inhibition of HIV and M. Tuberculosis Coinfection in Macrophages
    Stephen A Spector; Fiscal Year: 2010
    ..New approaches for treatment are needed that can inhibit Mtb, permit treatment of HIV without complex drug-drug interactions and are affordable in developing countries...
  23. Antimalarial Pharmacology in HIV Coinfected Children and Pregnant Women in Uganda
    Sunil Parikh; Fiscal Year: 2013
    ..and/or metabolism via cytochrome p450 pathways and are susceptible to physiological differences and drug-drug interactions with ARTs...
  24. Novel antifungals for Immunocompromised/HIV patients.
    ESTEBAN EDWARD MENA; Fiscal Year: 2011
    ..infections, but these medications are hampered by drug resistance, pharmacological limitations, and negative drug interactions. Also, the challenge continues to complicate by a changing epidemiology of fungal pathogen...
  25. Development of Estrogen Receptor B Selective Receptor Agonists to Treat Neuropath
    ETHAN SAMUEL BURSTEIN; Fiscal Year: 2012
    ..candidate: no apparent cardiovascular liability or mutagenicity risks, and little or no potential for drug-drug interactions. No apparent side effects were seen in rats receiving doses 10x above maximally effective doses...
  26. 3/3 CBT for Anxiety Disorders in Autism: Adapting Treatment for Adolescents
    JILL EHRENREICH MAY; Fiscal Year: 2010
    ..g., limited efficacy in this population, side effects, and potential drug x drug interactions)...
  27. 2/3 CBT for Anxiety Disorders in Autism: Adapting Treatment for Adolescents
    Eric A Storch; Fiscal Year: 2010
    ..g., limited efficacy in this population, side effects, and potential drug x drug interactions)...
  28. HEME PROTEIN REDUCTASES
    Stephen G Sligar; Fiscal Year: 2012
    ..of P450s involved in human drug metabolism, the detailed enzymology behind clinically important drug- drug interactions, the identity of heme-oxygen intermediate states in the catalytic cycle and the fate of reducing equivalents ..
  29. SMART HAND
    Larisa Y Poluektova; Fiscal Year: 2013
    ..Third, drug pharmacokinetic, pharmacodynamics, drug-drug interactions can be measured by employing PXR humanization (the androstane receptor with replacement of the mouse Cyp3a ..
  30. Phase I Study in Patients Supporting IV TPM for Neonatal Seizures (9/07, IND7899)
    James Cloyd; Fiscal Year: 2009
    ..with serious adverse effects including further brain injury, acute systemic toxicity, and significant drug interactions. The National Institute of Neurological Disorders and Stroke has identified improved treatment of neonatal ..
  31. HTS for Regulated Muscle Thin Filament Function.
    JAMES DOUGLAS POTTER; Fiscal Year: 2010
    ..to identify compounds that specifically alter the RTF Ca2+ sensitivity and not the force via cross bridge-drug interactions. To achieve our goals, this proposal will pursue two Specific Aims...
  32. Rhodiola Rosea Extracts, Salidroside and Bladder Cancer Chemoprevention
    Xiaolin Zi; Fiscal Year: 2012
    ..Rhodiola rosea extracts (RRE) have been the subject of clinical studies with no reported side effects or drug interactions. Our published data have demonstrated that the RRE increased the mean and maximum life-span of the fruit fly ..
  33. The optimization of compounds that selectively inhibit protein synthesis for the
    CATHY A SWINDLEHURST; Fiscal Year: 2013
    ..on these first in-class therapeutics to identify potential cardiac and hemolytic risks and identify potent drug interactions;to further delineate the mechanism-of-action by which these drugs effectively kill cancer cells in TNBC ..
  34. 1/3 CBT for Anxiety Disorders in Autism: Adapting Treatment for Adolescents
    Jeffrey Wood; Fiscal Year: 2010
    ..g., limited efficacy in this population, side effects, and potential drug x drug interactions)...
  35. Blood-to-CNS Drug Uptake in Pain
    THOMAS PAUL DAVIS; Fiscal Year: 2013
    ..Additionally, pain management regimens may involve multiple drugs, which can lead to harmful drug-drug interactions. These drug-drug interactions may involve changes in BBB transport mechanisms associated with functional ..
  36. Prevention of Prostate Cancer by Sulforaphane
    Shivendra Singh; Fiscal Year: 2013
    ..anticancer effect of SFN (Aim 1) resides in regimen optimization to eliminate potential adverse drug-drug interactions between SFN and other anti-oxidants...
  37. New treatment for androgen sensitive and resistant prostate cancer
    Angela M Brodie; Fiscal Year: 2013
    ..Kidney cells and minimal effects on a panel of cytochrome P450 enzymes commonly used to predict drug-drug interactions. An IND has been approved by the FDA and phase 1 trials began in November, 2010 using the micronized oral ..
  38. CLINICAL THERAPEUTICS
    Mark J Ratain; Fiscal Year: 2013
    ..regarding basic principles: pharmacodynamics and pharmacokinetics, drug disposition and metabolism, drug interactions, and various assay methodologies. Mark J. Ratain, M.D...
  39. Enzyme Environmental Effects in Complex Cytochrome P450-Catalyzed Reactions
    John C Hackett; Fiscal Year: 2013
    ..Due to their central role in xenobiotic disposition, CYPs mediate many adverse drug interactions of therapeutic significance...
  40. Herb-Drug Glucuronidation Interactions
    Reginald F Frye; Fiscal Year: 2011
    ..Accordingly, serious adverse herb- drug interactions resulting from the induction or inhibition of cytochrome P450 enzymes and/or the efflux transporter P-..
  41. P450-Mediated Dehydrogenation Mechanisms
    Garold S Yost; Fiscal Year: 2013
    ..are chemicals that ideally have beneficial effects with few side effects, and that don't have drug/drug interactions, which is when they act together to cause the medicines to lose their efficacy...
  42. Regulation of CYP proteins by reactive nitrogen species
    Edward T Morgan; Fiscal Year: 2012
    ..3) To study the down-regulation of rat hepatic CYP2B enzymes in vivo, and its consequences for drug-drug interactions. Rats will be administered NO donors and we will study the down-regulation of CYP2B enzymes in association ..
  43. Prescription Psychotherapeutic Drug Use Among Older Adults
    Yu Ping Chang; Fiscal Year: 2011
    ..adults are particularly susceptible to adverse medical outcomes from prescription drug abuse, as well as drug interactions due to age-related physiologic changes in body composition and drug metabolism...
  44. Stents and Antiplatelet Drugs: Impact on Ischemia and Bleeding in the Elderly
    Samip Vasaiwala; Fiscal Year: 2011
    ..than the relatively healthier population in randomized trials, thereby putting them at higher risk of drug-drug interactions and unwanted bleeding...
  45. Single Agents with Designed Combination Chemotherapy Potential
    Aleem Gangjee; Fiscal Year: 2010
    ..Pharmacokinetic differences of two or more drugs, drug-drug interactions, overlapping toxicities, cost of multiple drugs and patient compliance are important facets of combination ..
  46. Human Cytochrome P450 4F Enzymes and Drug Interactions
    ZHUO MICHAEL WANG; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Drug-drug interactions play an important role in clinical adverse events due to the wide prevalence of multi-drug therapies...
  47. PK/PD Issues in the Use of New Therapies for the Treatment of Tuberculosis
    Kelly E Dooley; Fiscal Year: 2013
    ..It is metabolized by the cytochrome P450 isoenzyme 3A4 (CYP3A4), so drug interactions with agents used to treat human immunodeficiency virus (HIV) are likely...
  48. Transcranial Direct Current Stimulation in the Management of Post-operative Pain
    Jeffrey J Borckardt; Fiscal Year: 2013
    ..or other residue, and can be delivered with minimal discomfort and without problems associated with drug-drug interactions. In two preliminary studies, the investigators have found that tDCS can reduce post-operative PCA use by as ..
  49. University of Iowa Older Adults CERT
    Elizabeth A Chrischilles; Fiscal Year: 2010
    ..the elderly is strong, barriers to guideline adherence are more prevalent in the elderly including drug-to-drug interactions, drug-disease contraindications, alterations in decision-making capacities, and compounded adverse event ..
  50. Drug-Drug Interactions and Preventable Adverse Events in Rheumatology
    CECILIA PILAR CHUNG; Fiscal Year: 2013
    ..An important target for interventions to decrease such severe adverse events is drug-drug interactions. Particularly important are drug interactions mediated by CYP3A, the cytochrome P-450 (CYP) member that is ..
  51. Assay development to discover therapeutics against human cytomegalovirus
    Domenico Tortorella; Fiscal Year: 2013
    ..A major draw-back to these drugs is their toxicity, drug-drug interactions, and the development of drug resistance strains of the virus upon prolonged treatment...
  52. SYNTHESIS AND BIOTRANSFORMATION OF ANTI-HIV PRODRUGS
    Chung K Chu; Fiscal Year: 2010
    ..potency, development of resistant virus, poor pharmacokinetics, lack of penetration into virus reservoirs, drug interactions affecting safety of the drug, oral bioavailability, and poor compliance by HIV infected patients...
  53. Mechanisms Underlying Drug-Diet Interactions
    Mary F Paine; Fiscal Year: 2013
    ..of drug interaction liability for these substances is not required prior to marketing;compared to drug-drug interactions, drug-diet interactions remain understudied, underreported, and misunderstood...
  54. Regulation of drug metabolizing enzymes by miRNAs
    Todd C Skaar; Fiscal Year: 2012
    ..These studies should help us better understand the interindividual variability in drug responses, and consequently improve drug therapies. ..
  55. CYP2B6 genetic variations and drug interactions
    Zeruesenay Desta; Fiscal Year: 2013
    ..are compromised by the extensive interindividual variability in CYP2B6 activity and its associated drug interactions. We discovered and validated clinically relevant novel substrate, inhibitors and genetic markers that now ..
  56. Arizona Center for Education and Research on Therapeutics
    Raymond L Woosley; Fiscal Year: 2010
    ..AzCERT has six years of experience in the prevention of adverse drug reactions (ADDRs) associated with drug-drug interactions (DDIs), especially those that harm women...
  57. Ex Vivo Model for Assessing the Vaginal Disposition of PrEP Antiretrovirals
    MARC MICHAEL BAUM; Fiscal Year: 2013
    ..Combination drug therapy often introduces complex drug-drug interactions that can result in toxic or sub-therapeutic drug concentrations and compromise treatment...
  58. Central Nervous System Delivery of Opioid Peptides
    JOHN HOEKMAN; Fiscal Year: 2012
    ..traditional mu-opioid analgesics presents numerous problems, including gastrointestinal side effects, drug-drug interactions with other CNS depressants, and physical dependence...
  59. Pharmacokinetics and Pathogenesis of Treatment Responses
    MIGUEL A GOICOECHEA; Fiscal Year: 2010
    ..Potentially, intracellular drug interactions or suboptimal pharmacokinetics during nucleoside therapy may explain, in part, why as many as 30% of ..
  60. ADDICTION THERAPY: METABOLISM AND TRANSPORT-MEDIATED DRUG INTERACTIONS
    Evan D Kharasch; Fiscal Year: 2012
    ..therapy (HAART) for HIV/AIDS causes clinically significant, complex, and insufficiently understood drug interactions with both methadone and buprenorphine, which may cause opiate withdrawal, toxicity, and treatment failures...
  61. High throughput cell-free ion channel screening workstation
    Jason L Poulos; Fiscal Year: 2013
    ..As a result, unintended drug interactions with ion channels are also of critical importance, requiring the screening of all drug candidates against ..
  62. Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children
    AWEWURA JACOB KWARA; Fiscal Year: 2013
    ..The treatment of TB, as well as TB/HIV coinfection in children is complicated by poor drug absorption, drug-drug interactions, high pill burden and lack of appropriate formulations...
  63. Cellular Efflux and Metabolism of Protease Inhibitors
    Ashim Mitra; Fiscal Year: 2004
    ..Our proposed theoretical model may predict, a priori, the extent of drug absorption and more importantly drug interactions among four WCS classes...
  64. Mixture Modeling: Pesticide Drug Interactions
    Charles Timchalk; Fiscal Year: 2009
    ..It is fully anticipated that this approach will facilitate the understanding of a variety of complex chemical interactions as it relates to the occupational health implications of working with insecticides. ..
  65. Drug Interactions and Bioavailability of Cranberry
    Jennifer Donovan; Fiscal Year: 2005
    ..The specific aims of this research are 1) to evaluate the potential for CB-drug interactions and 2) to determine the pharmacokinetics and renal clearance of four major CB flavonoids...
  66. The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology
    Christina L Aquilante; Fiscal Year: 2010
    ..the study proposed within this application is to elucidate the pharmacogenetics, pharmacokinetics, and drug-drug interactions of sitagliptin therapy...
  67. TDM & Drug Interactions in HIVinfected Substance Abusers
    Gene Morse; Fiscal Year: 2007
    This application describes an innovative approach to the rapid assessment of complex drug interactions between protease inhibitors and nonnucleoside reverse transcriptase inhibitors (NNRTIs), and commonly prescribed medications including ..
  68. Development of a disposable shippable chip for high throughput ion channel screen
    JASON POULOS; Fiscal Year: 2009
    Ion channels are important drug targets and unintended drug interactions with ion channels are also of critical importance, requiring the screening of all drug candidates...
  69. The Role of Statin Lactones in Statin Toxicity
    Uwe Christians; Fiscal Year: 2006
    ..A recent example stressing the clinical importance of statin/fibrate drug interactions is the removal of cerivastatin from the market on August 8, 2001 after at least 40 fatal cases of ..
  70. REDUCED DRUG INTERACTIONS OF AZOLE ANTIFUNGAL DRUGS
    Joseph Gal; Fiscal Year: 2003
    ..oral antifungal agents, but the use of these drugs is limited by adverse side effects and serious drug-drug interactions. The antifungal activity of the azoles is based on the inhibition of a fungal cytochrome P450 (CYP) enzyme, ..
  71. P-113: a novel peptide therapy for vaginal candidiasis
    David Osborne; Fiscal Year: 2005
    ..Azole therapy is also associated with drug interactions and serious side-effects...
  72. Reducing Adverse Self-Medication Behaviors in Older Adults with Hypertension
    Patricia Neafsey; Fiscal Year: 2007
    ..2) To show that APRNs will increase: a) knowledge concerning potential drug interactions arising from older adults' self-medication practices; b) self-efficacy for teaching older adults about ..
  73. AGING EFFECT ON DRUG BIOAVAILABILITY
    Stephen Hall; Fiscal Year: 1999
    ..In part due to the polypharmacy that the elderly experience, there is a high incidence of drug-drug interactions in this group which is also particularly vulnerable to drug toxicity...
  74. Electropulsation mediated drug therapy for Onychomycosis
    SATHYANARAYANA MURTHY; Fiscal Year: 2009
    ..generally associated with serious adverse effects independent of or associated with a number of significant drug interactions. Topical monotherapy is "less successful" in treating onychomycosis due to poor trans-nail permeation of ..
  75. Influence of Heme on Hepatic Cytochrome P450 Synthesis and Degradation
    Maria Correia; Fiscal Year: 2007
    ..Such drug-mediated modulation of P450 content is known to significantly influence clinical drug-drug interactions. Because P450 synthesis requires heme, defective heme synthesis as in the genetically inherited, acute heme-..